Kyverna Therapeutics, Inc. (KYTX)

7.33 +0.06 (+0.83%) As of 02:03PM EDT. Market open.

Kyverna Therapeutics, Inc.

5980 Horton Street
Suite 550
Emeryville, CA 94608
United States
(510) 925-2492
https://kyvernatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 100

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peter Maag Ph.D.	CEO & Director	709.99k	N/A	1967
Ms. Karen Walker	Chief Technology Officer	561.64k	N/A	1962
Dr. James Chung M.D., Ph.D.	Chief Medical Officer	645.62k	N/A	1968
Mr. Ryan Jones M.B.A.	Chief Financial Officer	N/A	N/A	1988
Dr. Tom Van Blarcom Ph.D.	Senior VP & Head of Research	N/A	N/A	N/A
Ms. Portia Serame	Vice President of Human Resources	N/A	N/A	N/A
Dr. Dominic Borie M.D., Ph.D.	President of Research & Development	N/A	N/A	1963
Mr. Devin Murray	Senior Vice President of Partnerships & Alliances	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Corporate governance

Kyverna Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.